SCHEMBL26628409

SCHEMBL26628409

CNC(=O)[C@H]1O[C@H](n2cnc3c(NCc4ccccn4)nc(-c4cncc(OC)c4)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 14/20 0.55
ADORA1 P30542 10/20 0.55
ADORA2A P29274 9/20 0.55
ADORA2B P29275 6/20 0.55
MAPK1 P28482 3/20 0.51
TP53 P04637 2/20 0.51
MAPT P10636 2/20 0.51
HTR2C P28335 1/20 0.51
PPARG P37231 1/20 0.51
HTR2B P41595 1/20 0.51
PPARD Q03181 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
CYP1A2 P05177 1/20 0.51
NPC1 O15118 1/20 0.50
GMNN O75496 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
THRB P10828 1/20 0.50
HPGD P15428 1/20 0.50
BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29762087 1.00 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL30850619 1.00 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL29073777 1.00 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL26628462 1.00 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL29073776 1.00 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL24600929 1.00 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL26628591 0.95 ADORA3 (0.48) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL30850480 0.95 ADORA3 (0.48) ADORA3ADORA1ADORA2AADORA2BMAPK1
SCHEMBL30850580 0.93 ADORA2A (0.57) ADORA3ADORA1ADORA2AADORA2BTSHR
SCHEMBL26628510 0.93 ADORA2A (0.57) ADORA3ADORA1ADORA2AADORA2BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2024-04-11 US claimed
EP-4273153-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2023-11-08 EP claimed
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2024-04-11 US disclosed
EP-4273153-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2023-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ADORA3, ADORA2A, ADORA2B ADORA3 1/4885ADORA1 4/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.